Clinical Trial Stage
Forecasted
The Clinical Trial Stage grant from the California Institute for Regenerative Medicine funds clinical trials of stem cell or genetic therapies for unmet medical needs, emphasizing access and diverse patient enrollment.
Funder: California Institute for Regenerative Medicine
Due Dates (Anticipated): October 2026: Mandatory consultation deadline | October 2026: Full application deadline | January 2027: Full application deadline | April 2027: Full application deadline | June 2027: Full application deadline | July 2027: Full application deadline
Funding Amounts: Up to $8M (for-profit, first-in-human) / $12M (non-profit, first-in-human); up to $15M (all other phases); max duration 4 years; co-funding required for some applicants.
Summary: Supports clinical trials (phases 1–3) of stem cell or genetic therapies for diseases with unmet needs, emphasizing broad access and commercialization strategy.
Key Information: Mandatory clinical development consultation required before application; quarterly deadlines; for-profit and non-profit organizations eligible.
Description
This program funds the clinical development of innovative stem cell-based or genetic therapies targeting diseases with significant unmet medical needs. Projects must propose an interventional phase 1, 2, or 3 clinical trial, with a comprehensive strategy for clinical development, patient access, and commercialization. The initiative emphasizes enrolling diverse patient populations reflective of the broader disease demographics and requires early planning for access and affordability once therapies are approved. Both California and non-California-based for-profit and non-profit organizations may apply, but non-California applicants face certain restrictions on allowable costs. The program provides not only funding but also strategic support and access to CIRM's clinical and manufacturing networks.
